Amarin | AMRN - Gross Profit On Sales

Stock Price
14.49
Daily Change
0.40 2.84%
Monthly
3.28%
Yearly
33.92%
Q1 Forecast
14.47

Amarin reported $22.21M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Alnylam Pharmaceuticals USD 1.05B 418.14M Sep/2025
Amarin USD 22.21M 28.15M Sep/2025
AstraZeneca USD 12.39B 406M Sep/2025
DBV Technologies USD 2.77M 33.21M Sep/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Ionis Pharmaceuticals USD 155M 293M Sep/2025
Neurocrine Biosciences USD 780.9M 104.7M Sep/2025
Novartis USD 10.82B 695M Sep/2025